Keros Therapeutics (KROS) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

Net selling: insiders sold $101K and bought $10K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$91K net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about KROS filings

Are insiders buying or selling Keros Therapeutics Inc (KROS) stock?

Net selling: insiders sold $101K and bought $10K of KROS stock on the open market in the 90 days to Nov 14, 2026, according to SEC Form 4 filings. $6K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Cho, Esther (Chief Legal Officer), who sold $46K. The latest filing was on Aug 20, 2026.

Which members of Congress have traded KROS recently?

None. No member of Congress disclosed a KROS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this KROS smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on KROS

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
Couldn't load this source
Insiders
Lean short3 sales · $95.5K
Form 4 filings, open market.
Congress
No recent politician filings found
Funds
- AQR, added +$5.9M, holdings at Jun 30
Lean long · thin1 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about KROS filings

Are insiders buying or selling Keros Therapeutics Inc (KROS) stock?

Net selling: insiders sold $101K and bought $10K of KROS stock on the open market in the 90 days to Nov 14, 2026, according to SEC Form 4 filings. $6K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Cho, Esther (Chief Legal Officer), who sold $46K. The latest filing was on Aug 20, 2026.

Which members of Congress have traded KROS recently?

None. No member of Congress disclosed a KROS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this KROS smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Funds

What funds are doing

1 move · 6 mo

Buys/Adds$5.9M

Buys/Adds (1)

AQ
AQR
Q2 2026 13F
$5.9M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in $1.56 a share above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

$0.70+$1.56 beat

-$0.86 expected

Revenue

$40.0M

SEC filing

EPS: Yahoo Finance

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	$0.70est. -$0.86	+$1.56beat	$40.0MSEC filing	+180.5%from $14.3M
Jun 30, 2026Reported Aug 3, 2026	-$1.45est. -$1.24	-16.75%miss	$0.00SEC filing	-100.0%from $18.2M
Mar 31, 2026Reported May 14, 2026	-$1.21est. -$0.92	-31.52%miss	$32.0KSEC filing	-100.0%from $211.2M
Dec 31, 2025Reported Mar 4, 2026	-$0.86est. -$0.45	-90.40%miss	$385.0KYahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 5, 2025	-$0.18est. -$1.11	+83.78%beat	$14.3MSEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 6, 2025	-$0.76est. -$1.13	+32.74%beat	$18.2MSEC filing	No year-ago quarter
Mar 31, 2025Reported May 6, 2025	$3.62est. $0.01	+$3.61beat	$211.2MSEC filing	No year-ago quarter
Dec 31, 2024Reported Feb 26, 2025	-$1.14est. -$0.43	-$0.71miss	$0.00 · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $9.51
High: $10.54
Low: $9.44
Prev close: $9.54
52-wk high: $22.55
52-wk low: $8.98
Mkt cap: $197.8M
ROE: -12.6%
Fwd P/E: 15.7x
Beta: 1.19
P/S: 4.9x
P/B: 0.7x
Profit margin: -151.4%
Op margin: -172.4%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -151.4%
Forward P/E: 15.65
Market cap: $198M

Valuation

P/S4.85
P/B0.67

Quality

Operating margin-172.4%
ROE-12.6%
ROA-8.4%

Growth

Beta1.19

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

34balanced

20D volatility

62%annualized

52-week range

$10.08

$8.98$22.55

20D support

$8.98recent floor

20D resistance

$11.88recent ceiling

Returns

5D +6.7%20D -9.2%60D -9.2%

Price vs moving averages

SMA20 -5.4%SMA50 -8.8%SMA200 -13.6%

Volume pace

1.03xvs prior 20D

Keros Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about KROS filings

Smart money on KROS

Questions about KROS filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $1.56 a share above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Keros Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about KROS filings

Smart money on KROS

Questions about KROS filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $1.56 a share above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Keros Therapeutics Inc

Overview

Questions about KROS filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Keros Therapeutics Inc

Overview

Questions about KROS filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.